# colorectal cancer - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 80862
- Completion tokens: 66364
- Reasoning tokens: 25729
- Total tokens: 147226
- API requests reported: 5
- Elapsed seconds: 57.409
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 4/5; original repeat 4; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The overall survival (OS) transcriptomic analysis in colorectal cancer (CRC) tissue reveals a clear dichotomy between mucosal lineage maintenance, metabolic coupling, and stromal/invasion-driven hazard programs. 

1. **Intestinal Lineage Preservation vs. Dedifferentiation**: Key intestinal epithelial transcription factors and polarity maintenance genes (such as **CDX2**, **CDX1**, **MYO5B**, and **LGALS4**) are strongly protective ($\text{HR} < 1$). Higher transcript levels of these markers correspond to retained epithelial differentiation, luminal polarization, and preserved mucosal architecture, which are consistently associated with longer overall survival.
2. **Stromal Remodeling, EMT, and TGF-$\beta$ Signaling**: Conversely, risk-associated genes ($\text{HR} > 1$) are heavily enriched for TGF-$\beta$ superfamily ligands (**INHBB**), epithelial-to-mesenchymal transition (EMT) lncRNAs (**ZEB1-AS1**, **MIR31HG**), extracellular matrix (ECM) cross-linkers (**ITGBL1**, **ADAMTS18**), and cytoskeletal elements (**TPM4**, **MAP1B**, **DCBLD2**). Elevated expression of this mesenchymal axis indicates stromal invasion, desmoplasia, and aggressive metastatic propensity.
3. **Mitochondrial Respiration and Metabolic Integrity**: Protective signals feature multiple core mitochondrial components spanning oxidative phosphorylation (**NDUFA9**, **ATP5B**, **ATP5G1**, **COA3**), TCA cycle/short-chain fatty acid utilization (**CS**, **ACSS2**, **OGDHL**, **GLYCTK**), and peroxisomal turnover (**PXMP2**). Loss or down-regulation of these metabolic programs marks a glycolytic, bioenergetically dysregulated phenotype associated with disease progression.
4. **Immunomodulation and Ecto-Enzymatic Signaling**: Immune-related signals include the immunosuppressive ecto-5'-nucleotidase **NT5E** (CD73; uploaded cohort $\text{HR} = 1.313$, $\text{FDR} = 0.03939$) conferring increased hazard, contrasted with protective antigen presentation accessory proteins (**TAPBPL**; uploaded cohort $\text{HR} = 0.711$, $\text{FDR} = 0.01921$) and anti-inflammatory/checkpoint lectins (**LGALS9**, **LGALS4**).

Because no external statistical replication dataset was provided in this entry, **external statistical validation was not performed** on an independent clinical cohort.

---

### 2. Core Biological Programs

```
                       Transcriptomic Survival Axis in CRC
                                        │
         ┌──────────────────────────────┴──────────────────────────────┐
         ▼                                                             ▼
Protective Programs (HR < 1)                               Risk-Associated Programs (HR > 1)
 ├─ Intestinal Lineage Differentiation                      ├─ ECM Remodeling, EMT & TGF-β Axis
 │   (CDX2, CDX1, MYO5B, LGALS4)                            │   (INHBB, ZEB1-AS1, ITGBL1, TPM4)
 ├─ Mitochondrial OXPHOS & Bioenergetics                    └─ Adenosinergic & Immunosuppressive Axis
 │   (NDUFA9, ATP5B, ATP5G1, CS, ACSS2)                         (NT5E, DCBLD2, ABL2, AKT3)
 └─ Antigen Processing & Mucosal Immunity
     (TAPBPL, LGALS9, CCDC134)
```

#### Program 1: Intestinal Lineage Differentiation & Epithelial Polarity Maintenance
* **Direction / Prognostic Association**: Protective-associated ($\text{HR} < 1$, lower risk of death).
* **Major Supporting Genes**: **CDX2** (uploaded cohort $\text{HR} = 0.7478$, $\text{FDR} = 0.0355$), **CDX1** (uploaded cohort $\text{HR} = 0.7809$, $\text{FDR} = 0.05735$), **MYO5B** (uploaded cohort $\text{HR} = 0.7483$, $\text{FDR} = 0.02823$), **LGALS4** (uploaded cohort $\text{HR} = 0.7712$, $\text{FDR} = 0.05123$), **RAB11FIP4** (uploaded cohort $\text{HR} = 0.7361$, $\text{FDR} = 0.03294$).
* **Standardized Pathway**: Reactome: *CDX2-dependent gene expression* / GO:0030061 (*Intestinal epithelial cell differentiation*).
* **Biological Explanation**: **CDX2** and **CDX1** act as master lineage transcription factors that enforce colonic epithelial identity and suppress Wnt/$\beta$-catenin-driven dedifferentiation ([PMID: 30631044]). **MYO5B** and **RAB11FIP4** coordinate apical recycling and brush border polarization, while **LGALS4** stabilizes epithelial cell-cell adhesion. High expression reflects well-differentiated, less invasive tumor cells.
* **Evidence Strength & Limitations**: High biological consistency across multiple lineage markers. However, reduced expression in bulk tumor transcriptomes may partially reflect lower tumor epithelial purity or increased stromal infiltration rather than cell-intrinsic down-regulation alone.

#### Program 2: ECM Remodeling, Epithelial-to-Mesenchymal Transition (EMT) & TGF-$\beta$ Signaling
* **Direction / Prognostic Association**: Risk-associated ($\text{HR} > 1$, higher risk of death).
* **Major Supporting Genes**: **INHBB** (uploaded cohort $\text{HR} = 1.433$, $\text{FDR} = 0.001093$), **ZEB1-AS1** (uploaded cohort $\text{HR} = 1.372$, $\text{FDR} = 0.008647$), **ITGBL1** (uploaded cohort $\text{HR} = 1.299$, $\text{FDR} = 0.03061$), **TPM4** (uploaded cohort $\text{HR} = 1.364$, $\text{FDR} = 0.00891$), **DCBLD2** (uploaded cohort $\text{HR} = 1.408$, $\text{FDR} = 0.008647$), **ADAMTS18** (uploaded cohort $\text{HR} = 1.263$, $\text{FDR} = 0.04681$), **MIR31HG** (uploaded cohort $\text{HR} = 1.309$, $\text{FDR} = 0.006636$).
* **Standardized Pathway**: Reactome R-HSA-9926550 (*Regulation of EMT and extracellular matrix*) / KEGG: *TGF-beta signaling pathway*.
* **Biological Explanation**: Activin subunit **INHBB** drives paracrine TGF-$\beta$ superfamily signaling ([Europe PMC: 41992239]). Long non-coding RNAs **ZEB1-AS1** and **MIR31HG** epigenetically promote ZEB1-driven EMT. Elevated expression of integrin-like **ITGBL1** and matrix metalloproteinases (**ADAMTS18**), together with cytoskeletal reorganizers (**TPM4**, **MAP1B**), reflects cancer-associated fibroblast (CAF) activation and enhanced cell motility.
* **Evidence Strength & Limitations**: Supported by top statistical significance in the dataset ($\text{FDR} \le 0.00891$). The principal limitation is the inability to distinguish cancer-cell-intrinsic EMT from cancer-associated stromal fibroblast density without single-cell or spatial resolution.

#### Program 3: Mitochondrial Respiration & Central Metabolic Coupling
* **Direction / Prognostic Association**: Protective-associated ($\text{HR} < 1$, lower risk of death).
* **Major Supporting Genes**: **NDUFA9** (uploaded cohort $\text{HR} = 0.6886$, $\text{FDR} = 0.008647$), **ATP23** (uploaded cohort $\text{HR} = 0.6885$, $\text{FDR} = 0.006636$), **ATP5B** (uploaded cohort $\text{HR} = 0.7483$, $\text{FDR} = 0.05931$), **ATP5G1** (uploaded cohort $\text{HR} = 0.7471$, $\text{FDR} = 0.05194$), **COA3** (uploaded cohort $\text{HR} = 0.7437$, $\text{FDR} = 0.04336$), **CS** (uploaded cohort $\text{HR} = 0.7545$, $\text{FDR} = 0.03875$), **ACSS2** (uploaded cohort $\text{HR} = 0.7577$, $\text{FDR} = 0.06021$), **OGDHL** (uploaded cohort $\text{HR} = 0.6858$, $\text{FDR} = 0.07443$).
* **Standardized Pathway**: KEGG: *Oxidative phosphorylation* (hsa00190) / Reactome: *The citric acid (TCA) cycle and respiratory electron transport* (R-HSA-1428517).
* **Biological Explanation**: **NDUFA9** (Complex I subunit), **COA3** (Complex IV assembly factor), **ATP5B**/**ATP5G1** (ATP synthase subunits), and **ATP23** (F1Fo-ATP synthase chaperone; [PMID: 17135288]) maintain electron transport chain (ETC) integrity. Citrate synthase (**CS**), **OGDHL**, and acetyl-CoA synthetase (**ACSS2**) sustain mitochondrial TCA cycle fluxes. Retention of mitochondrial metabolic competence marks metabolic quiescence and differentiated cellular states, whereas metabolic shutdown correlates with aggressive, hypoxic, fermentative tumors.
* **Evidence Strength & Limitations**: Multiple genes exhibit low hazard ratios ($\text{HR} \approx 0.68\text{--}0.76$). However, RNA expression of metabolic enzymes does not directly prove metabolic flux rates, which require metabolomic or functional bioenergetic assays.

#### Program 4: Immunomodulation and Ecto-Enzymatic Adenosinergic Axis
* **Direction / Prognostic Association**: Mixed / Context-dependent (Risk: **NT5E**; Protective: **TAPBPL**, **LGALS9**, **CCDC134**).
* **Major Supporting Genes**: **NT5E** (uploaded cohort $\text{HR} = 1.313$, $\text{FDR} = 0.03939$), **TAPBPL** (uploaded cohort $\text{HR} = 0.711$, $\text{FDR} = 0.01921$), **LGALS9** (uploaded cohort $\text{HR} = 0.7533$, $\text{FDR} = 0.04204$), **CCDC134** (uploaded cohort $\text{HR} = 0.7119$, $\text{FDR} = 0.02516$).
* **Standardized Pathway**: GO:2000404 (*Regulation of T cell migration*) / Reactome: *Antigen processing-Cross presentation*.
* **Biological Explanation**: Ecto-5'-nucleotidase (**NT5E**/CD73) converts AMP to extracellular adenosine, creating an immunosuppressive microenvironment that suppresses cytotoxic T lymphocyte and NK cell responses ([PMID: 36480312]). Conversely, **TAPBPL** (TAP Binding Protein Like) facilitates MHC class I antigen loading to preserve immune surveillance. **LGALS9** (Galectin-9) and cytokine-like **CCDC134** modulate local leukocyte trafficking and anti-tumor immunity.
* **Evidence Strength & Limitations**: Strong mechanistic rationale in tumor immunology. However, immune checkpoint dynamics are highly non-linear, and spatial localization relative to immune infiltrates cannot be determined from bulk transcriptomics.

---

### 3. Key Genes and Interaction Modules

| Candidate Gene / Module | Direction & Effect Size (Uploaded Cohort) | Core Program Role | Proposed Gene-Gene / Molecular Relationship |
| :--- | :--- | :--- | :--- |
| **INHBB** | Risk-Associated ($\text{HR} = 1.433$, $\text{FDR} = 0.001093$) | TGF-$\beta$ / Mesenchymal Signaling | **Pathway co-membership & ligand-receptor regulatory action**: Encodes Activin $\beta\text{B}$ subunit; signals via ACVR2B/ALK4 to induce SMAD2/3 transcription of EMT factors (**ZEB1-AS1**). |
| **CDX2** | Protective ($\text{HR} = 0.7478$, $\text{FDR} = 0.0355$) | Intestinal Lineage Differentiation | **Direct transcriptional regulatory interaction**: Transactivates intestine-specific differentiation genes (**MYO5B**, **LGALS4**) and suppresses Wnt target transcription ([PMID: 30631044]). |
| **NT5E (CD73)** | Risk-Associated ($\text{HR} = 1.313$, $\text{FDR} = 0.03939$) | Immunosuppressive Adenosinergic Axis | **Indirect enzymatic functional relationship**: Generates extracellular adenosine to inhibit immune effector function; co-expressed with stromal CAF markers (**ITGBL1**). |
| **NDUFA9 – ATP5B – ATP23 Module** | Protective (**NDUFA9**: $\text{HR} = 0.6886$; **ATP23**: $\text{HR} = 0.6885$; **ATP5B**: $\text{HR} = 0.7483$) | Mitochondrial Respiration (OXPHOS) | **Pathway co-membership & multi-protein complex assembly**: NDUFA9 (Complex I) and ATP5B/ATP23 (Complex V assembly chaperone [PMID: 17135288]) participate in the inner mitochondrial membrane respiratory chain. |
| **ZEB1-AS1 – MIR31HG Module** | Risk-Associated (**ZEB1-AS1**: $\text{HR} = 1.372$; **MIR31HG**: $\text{HR} = 1.309$) | EMT / Epigenetic Repression | **Co-expression & parallel regulatory interaction**: lncRNAs that epigenetically silence epithelial genes (e.g., *CDH1*) to drive stromal invasion. |
| **TAPBPL** | Protective ($\text{HR} = 0.711$, $\text{FDR} = 0.01921$) | Antigen Processing & Presentation | **Direct physical interaction & protein complex assembly**: Interacts with MHC class I molecules and TAP to edit peptides for CD8+ T cell immune recognition. |
| **ITGBL1** | Risk-Associated ($\text{HR} = 1.299$, $\text{FDR} = 0.03061$) | ECM Remodeling & CAF Dynamics | **Indirect microenvironmental relationship**: Secreted integrin-like protein that promotes myofibroblast differentiation and matrix stiffness. |
| **CS – ACSS2 Module** | Protective (**CS**: $\text{HR} = 0.7545$; **ACSS2**: $\text{HR} = 0.7577$) | Central Acetyl-CoA / TCA Cycle Metabolism | **Pathway co-membership & metabolic coupling**: CS initializes the TCA cycle; ACSS2 generates acetyl-CoA from acetate, maintaining metabolic homeostasis. |
| **MSLN** | Risk-Associated ($\text{HR} = 1.313$, $\text{FDR} = 0.04507$) | Cell Surface Adhesion & Signaling | **Direct physical interaction (literature)**: Cell surface glycoprotein that binds MUC16/CA125 to mediate cell adhesion and invasive signaling ([Europe PMC: 42363170]). |
| **DCBLD2** | Risk-Associated ($\text{HR} = 1.408$, $\text{FDR} = 0.008647$) | Receptor Tyrosine Kinase Crosstalk | **Regulatory & protein interaction**: Transmembrane scaffold protein that enhances EGFR/VEGFR receptor signaling and cell motility. |

---

### 4. Validation Priorities

#### 1. INHBB / TGF-$\beta$ Paracrine Axis as an Invasive Driver
* **Classification**: Mechanistic hypothesis.
* **Why Prioritize**: **INHBB** exhibits the lowest P-value and highest hazard ratio ($\text{HR} = 1.433$, $P = 1.999 \times 10^{-8}$, $\text{FDR} = 0.001093$) among single coding transcripts in the uploaded cohort dataset.
* **Current Input Dataset Evidence**: Strong positive association with overall mortality in CRC tumor tissue.
* **External Evidence**: Published functional studies demonstrate high INHBB expression drives malignant phenotypes and migration in colorectal cancer organoids ([Europe PMC: 41992239]).
* **Next Validation Step**: Knockdown/overexpression of INHBB in patient-derived CRC organoids followed by Matrigel invasion assays and downstream SMAD phosphorylation analysis.
* **Current Conclusion Status**: **Supported hypothesis**.

#### 2. Ecto-5'-Nucleotidase (NT5E/CD73) Immune Evasion Mechanism
* **Classification**: Therapeutic target / Biomarker.
* **Why Prioritize**: **NT5E** is an actionable cell-surface enzyme targeting tumor-induced immunosuppression.
* **Current Input Dataset Evidence**: Significant risk association in uploaded cohort ($\text{HR} = 1.313$, $\text{FDR} = 0.03939$).
* **External Evidence**: Broad literature supports CD73 as a prognostic biomarker and candidate for therapeutic antibody blockade in solid tumors ([PMID: 36480312]).
* **Next Validation Step**: Multiplex immunohistochemistry / spatial transcriptomics in CRC tissue microarrays to correlate CD73 tumor/stromal cell density with CD8+ T-cell infiltration and survival.
* **Current Conclusion Status**: **Supported hypothesis**.

#### 3. Loss of Epithelial Differentiation (CDX2/MYO5B) vs. Tumor Purity Confounding
* **Classification**: Confounding or composition check.
* **Why Prioritize**: Differentiates whether low **CDX2** (uploaded cohort $\text{HR} = 0.7478$, $\text{FDR} = 0.0355$) reflects true intrinsic epithelial dedifferentiation or low tumor epithelial cell fraction.
* **Current Input Dataset Evidence**: Concordant protective signal across multiple mucosal epithelial markers (**CDX2**, **CDX1**, **MYO5B**, **LGALS4**).
* **External Evidence**: CDX2 loss is clinically established as a poor prognosis marker in Stage II/III CRC ([PMID: 30631044]).
* **Next Validation Step**: Multivariable Cox regression adjusting for histopathological tumor purity, CMS subtype, and stromal content metrics (e.g., ESTIMATE or single-cell deconvolution).
* **Current Conclusion Status**: **Established evidence** (for clinical prognostic association); **Exploratory hypothesis** (for cell-intrinsic vs. composition-driven mechanism in this specific cohort).

#### 4. Mitochondrial Respiration (NDUFA9/ATP23) Metabolic Protection Axis
* **Classification**: Mechanistic hypothesis.
* **Why Prioritize**: Uncovers why elevated OXPHOS/mitochondrial assembly transcripts (**NDUFA9**: uploaded cohort $\text{HR} = 0.6886$; **ATP23**: uploaded cohort $\text{HR} = 0.6885$) strongly correlate with favorable overall survival.
* **Current Input Dataset Evidence**: Co-directional protective association across multiple ETC complexes and metabolic enzymes.
* **External Evidence**: ATP23 functions as an F1Fo-ATP synthase chaperone ([PMID: 17135288]), and OXPHOS expression inversely correlates with aggressive Warburg-like CRC subtypes.
* **Next Validation Step**: Measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) via Seahorse assay in CRC cell lines stratified by NDUFA9/ATP23 expression.
* **Current Conclusion Status**: **Supported hypothesis**.

#### 5. Mesothelin (MSLN) Targeting via Immunotherapy
* **Classification**: Therapeutic target.
* **Why Prioritize**: **MSLN** (uploaded cohort $\text{HR} = 1.313$, $\text{FDR} = 0.04507$) encodes a cell-surface antigen targetable by CAR-T or antibody-drug conjugates.
* **Current Input Dataset Evidence**: Increased hazard associated with elevated MSLN transcript levels.
* **External Evidence**: Preclinical models confirm mesothelin-targeted CAR-T cells exhibit potent cytotoxicity in 3D patient-derived CRC organoids ([Europe PMC: 42363170]).
* **Next Validation Step**: Screen CRC clinical samples for MSLN protein surface intensity by flow cytometry and immunohistochemistry to establish threshold expression for CAR-T sensitivity.
* **Current Conclusion Status**: **Exploratory hypothesis** (therapeutic efficacy cannot be inferred solely from bulk survival risk).

---

### 5. Evidence Grounding

```
                             Hierarchy of Evidence Support
                                           │
         ┌─────────────────────────────────┼─────────────────────────────────┐
         ▼                                 ▼                                 ▼
Direct Dataset Signals           Pathway & Interaction Records      Literature & Clinical Records
 ├─ INHBB (HR=1.433, FDR=0.001093)├─ OXPHOS (KEGG hsa00190)          ├─ INHBB in CRC (Europe PMC: 41992239)
 ├─ SCARA3 (HR=1.377, FDR=0.002434)├─ CDX2 Targets (Reactome)         ├─ CDX2 / Wnt (PMID: 30631044)
 ├─ NDUFA9 (HR=0.6886, FDR=0.008647)├─ Intact/STRING Networks       ├─ CD73/NT5E (PMID: 36480312)
 └─ TAPBPL (HR=0.711, FDR=0.01921)└─ TRRUST Regulatory Actions       └─ MSLN CAR-T (Europe PMC: 42363170)
```

The evidence supporting the interpretations is categorized across distinct, explicitly evaluated modalities:

1. **Direct Input Dataset Evidence**:
   * Survival hazard ratios, P-values, and false discovery rates derived from bulk tumor transcriptomics represent the *only* statistical evidence computed directly on this patient cohort.
   * High-confidence risk markers with $\text{FDR} < 0.01$: **INHBB**, **SCARA3**, **MIR31HG**, **ZEB1-AS1**, **DCBLD2**, **TPM4**.
   * High-confidence protective markers with $\text{FDR} < 0.01$: **ATP23**, **NDUFA9**.
2. **Pathway and Gene-Gene Interaction Records**:
   * Standardized pathway annotations (KEGG, Reactome, GO) link individual candidate transcripts to higher-order functional networks.
3. **Literature & Clinical Records**:
   * Extrapolations to therapeutic efficacy or cellular mechanistics rely on external peer-reviewed literature and functional assays.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=9, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
